Values for total white blood cells, neutrophils, lymphocytes, platelet counts, platelet-to-lymphocyte ratios, and neutrophil-to-lymphocyte ratios in recurrent hepatocellular carcinoma patients (n = 132).

<p>Values for total white blood cells, neutrophils, lymphocytes, platelet counts, platelet-to-lymphocyte ratios, and neutrophil-to-lymphocyte ratios in recurrent hepatocellular carcinoma patients (n = 132).</p

The receiver operating characteristics curves for 0.5-year overall survival in NLR and PLR patients.

<p>The difference between groups were not statistically significant (<i>P</i> = 0.4704). PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p

The receiver operating characteristics curves for 2-year overall survival in NLR and PLR.

<p>The difference between groups were not statistically significant (<i>P</i> = 0.7875). PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p

Overall survival curves in patients with low and high NLR.

<p>The difference between groups were statistically significant (log-rank test, <i>P</i> = 0.017). PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p

Cox proportional hazards model of baseline prognosticators for overall survival in 132 patients with RHCC undergoing TACE.

<p>Cox proportional hazards model of baseline prognosticators for overall survival in 132 patients with RHCC undergoing TACE.</p

The receiver operating characteristics curves for 1-year overall survival in NLR and PLR patients.

<p>The difference between groups were statistically significant (<i>P</i> = 0.0295). PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p

Comparison of clinicopathologic and demographic features between patients with low NLR and high NLR expressed as mean ± SD or n.

<p>Comparison of clinicopathologic and demographic features between patients with low NLR and high NLR expressed as mean ± SD or n.</p

Overall survival curves in low and high platelet-to-lymphocyte ratio patients.

<p>The difference between groups were statistically significant (log-rank test, <i>P</i> = 0.030). PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p

DataSheet_1_Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.docx

BackgroundAlthough peripheral blood lymphocyte subsets, particularly PD-1+ T cells, are promising prognostic indicators for patients with cancer. However, their clinical significance remains unclear.MethodsWe prospectively enrolled 157 patients with hepatocellular carcinoma (HCC) treated with transcatheter arterial chemoembolization combined with or without PD-1 inhibitors. Twenty peripheral lymphocyte subsets and cytokines were analyzed. We analyzed the differences in PD-1+ T cells between patients treated with and without PD-1 inhibitors and their associations with tumor response, survival prognosis, and clinical features.ResultsWe found that the baseline CD8+PD-1+ and CD4+PD-1+ T-cell frequencies in patients who had received PD-1 inhibitors were lower than those in patients who had not received PD-1 inhibitors (p 0.05), whereas in the latter patients, the levels of CD8+PD-1+ T cells, CD4+PD-1+ T cells, and CD8+PD-1+/CD4+PD-1+ ratio did not predict tumor response, progression-free survival (PFS), or overall survival (OS) (p>0.05). Furthermore, in multivariate analysis of patients treated with or without PD-1 inhibitors revealed that the levels of CD8+CD38+ T cells (OR = 2.806, p = 0.006) were associated with tumor response, whereas those of CD8+CD28+ T cells (p = 0.038, p = 0.001) and natural killer (NK) cells (p = 0.001, p = 0.027) were associated with PFS and OS. Although, these independent prognostic factors were associated with progressive tumor characteristics (p 0.05).ConclusionCirculating CD8+CD38+ T cells, CD8+CD28+ T cells, and NK cells were identified as potential prognostic factors for tumor response and survival in patients with HCC. Contrastingly, although PD-1 inhibitors can effectively block the T cell PD-1 receptor, the baseline PD-1+ T-cell frequencies and changes in the frequency of these cells have limited prognostic value.</p

Additional file 6 of Transcriptome sequencing and metabolome analysis reveal the metabolic reprogramming of partial hepatectomy and extended hepatectomy

Additional file 6: Figure S3. Metabolomic cluster dendrogram of different samples